Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 7/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | THRB | P10828 | 1/20 | 0.69 |
| ▸ | MTOR | P42345 | 1/20 | 0.69 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.69 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.69 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | GLA | P06280 | 1/20 | 0.67 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.64 |
| ▸ | ST6GAL1 | P15907 | 5/20 | 0.64 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cytarabine 5'-Phosphate SCHEMBL20277485 | 1.00 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL14669262 | 1.00 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL207204 | 1.00 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL17934719 | 1.00 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL11217191 | 1.00 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL16189 | 1.00 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL6115643 | 1.00 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL2681941 | 1.00 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL18785109 | 1.00 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL29450798 | 1.00 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 682 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4722240-A1 | COMBINATION OF ANTIBODIES, OR ANTIGEN-BINDING FRAGMENTS THEREOF, FOR THE TREATMENT OF CANCERS AND COMPOSITIONS THEREOF | Xenothera (FR) | 2026-04-08 | — | — | EP | claimed |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | claimed |
| WO-2025073856-A1 | COMBINATION OF ANTIBODIES, OR ANTIGEN-BINDING FRAGMENTS THEREOF, FOR THE TREATMENT OF CANCERS | XENOTHERA (FR) | 2025-04-10 | — | — | WO | claimed |
| WO-2024229600-A1 | SOLUBLE BIOMOLECULAR GLASS AND USE THEREOF | 中国科学院过程工程研究所 | 2024-11-14 | — | — | WO | claimed |
| EP-4242295-B1 | B. AMYLOLIQUEFACIENS STRAIN AND THERAPEUTIC USE | ARTUGEN THERAPEUTICS LTD (IE) | 2024-08-28 | — | — | EP | claimed |
| EP-4242294-B1 | B. AMYLOLIQUEFACIENS STRAIN AND THERAPEUTIC USE | ARTUGEN THERAPEUTICS LTD (IE) | 2024-08-21 | — | — | EP | claimed |
| US-11896628-B2 | Methods and compositions for the treatment of C. difficile | ARTUGEN THERAPEUTICS LTD. (IE) | 2024-02-13 | — | — | US | claimed |
| CN-117007527-A | Colorimetric sensor array based on CuMOFs and preparation method and application thereof | 曲阜师范大学 | 2023-11-07 | — | — | CN | claimed |
| EP-4242295-A2 | B. AMYLOLIQUEFACIENS STRAIN AND THERAPEUTIC USE | Artugen Therapeutics Ltd. (IE) | 2023-09-13 | — | — | EP | claimed |
| EP-4242294-A2 | B. AMYLOLIQUEFACIENS STRAIN AND THERAPEUTIC USE | Artugen Therapeutics Ltd. (IE) | 2023-09-13 | — | — | EP | claimed |
| US-20030162164-A1 | Comparative phenotype analysis of cells, including testing of biologically active compounds | BIOLOG, INC. | 2003-08-28 | — | — | US | claimed |
| EP-1307467-A1 | METHOD OF SEPARATING NUCLEOSIDE PHOSPHATES | ISIS INNOVATION LIMITED (GB) | 2003-05-07 | — | — | EP | claimed |
| US-20020064836-A1 | PROCESSES FOR PRODUCING SUGAR NUCLEOTIDES AND COMPLEX CARBOHYDRATES | KYOWA HAKKO BIO CO., LTD. (JP) | 2002-05-30 | — | — | US | claimed |
| US-20020025560-A1 | Processes for producing sugar nucleotides and complex carbohydrates | KYOWA HAKKO BIO CO., LTD. (JP) | 2002-02-28 | — | — | US | claimed |
| WO-2002012255-A1 | METHOD OF SEPARATING NUCLEOSIDE PHOSPHATES | ISIS INNOVATION LIMITED (GB) | 2002-02-14 | — | — | WO | claimed |
| EP-0870841-A1 | PROCESSES FOR PRODUCING SUGAR NUCLEOTIDES AND COMPLEX CARBOHYDRATES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1998-10-14 | — | — | EP | claimed |
| EP-0470969-B1 | PROCESS FOR THE SEPARATION AND PURIFICATION OF SIALYL TRANSFERASES | ALBERTA RESEARCH COUNCIL (CA) | 1993-08-04 | — | — | EP | claimed |
| US-4591564-A | Transferase enzymes which modify the 3'-termini of ribonucleic acid and methods | THE UNIVERSITY OF MONTANA (US) | 1986-05-27 | — | — | US | claimed |
| US-4577012-A | ABSORPTION ON ACTIVATED CARBON, ELUTION WITH ALKALI HYDROXIDE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1986-03-18 | — | — | US | claimed |
| US-RE28886-E | Method for preparing cytidine diphosphate choline | KYOWA HAKKO KOGYO CO., LTD. (JA) | 1976-06-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | P2RY2 3116/4885LMNA 240/4885THRB 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.